{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T22:32:55Z","timestamp":1788993175802,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T00:00:00Z","timestamp":1531699200000},"content-version":"vor","delay-in-days":76,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009655","name":"Sunovion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.yebeh.2017.12.017","type":"journal-article","created":{"date-parts":[[2018,3,28]],"date-time":"2018-03-28T19:52:50Z","timestamp":1522266770000},"page":"119-127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Psychiatric and cognitive adverse events: A pooled analysis of three phase III trials of adjunctive eslicarbazepine acetate for partial-onset seizures"],"prefix":"10.1016","volume":"82","author":[{"given":"Eva","family":"Andermann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Biton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selim R.","family":"Benbadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassel","family":"Shneker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aashit K.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Carre\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugen","family":"Trinka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elinor","family":"Ben-Menachem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Biraben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Gama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Blum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2017.12.017_bb0005","series-title":"Wyllie's treatment of epilepsy: principles and practice","first-page":"1037","article-title":"Psychiatric comorbidity of epilepsy","author":"Leeman","year":"2011"},{"key":"10.1016\/j.yebeh.2017.12.017_bb0010","series-title":"Jasper's basic mechanisms of the epilepsies","article-title":"Cognitive and behavioral co-morbidities of epilepsy","author":"Kleen","year":"2012"},{"key":"10.1016\/j.yebeh.2017.12.017_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yebeh.2011.03.011","article-title":"Antiepileptic drugs in the treatment of psychiatric disorders","volume":"21","author":"Kaufman","year":"2011","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2017.12.017_bb0020","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1212\/01.wnl.0000247045.85646.c0","article-title":"Psychotropic effects of antiepileptic drugs","volume":"67","author":"Ettinger","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2017.12.017_bb0025","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1528-1167.2012.03688.x","article-title":"Antiepileptic drugs and suicidality: an expert consensus statement from the Task Force on Therapeutic Strategies of the ILAE Commission on Neuropsychobiology","volume":"54","author":"Mula","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.12.017_bb0030","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S1474-4422(12)70153-9","article-title":"Adverse effects of antiepileptic drugs","volume":"11","author":"Perucca","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2017.12.017_bb0035","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1046\/j.1528-1157.44.s4.3.x","article-title":"Newer antiepileptic drugs and cognitive issues","volume":"44","author":"Aldenkamp","year":"2003","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.12.017_bb0040","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1528-1167.2008.01946.x","article-title":"Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study","volume":"50","author":"Elger","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.12.017_bb0045","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.eplepsyres.2010.01.014","article-title":"Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy","volume":"89","author":"Ben-Menachem","year":"2010","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2017.12.017_bb0050","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/epi.12894","article-title":"Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: results of a phase III, double-blind, randomized, placebo-controlled trial","volume":"56","author":"Sperling","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.12.017_bb0055","first-page":"209","article-title":"Eslicarbazepine acetate as adjunctive treatment for refractory partial-onset seizures: pooled analysis of safety data from three phase III controlled trials","volume":"14","author":"Rogin","year":"2014","journal-title":"Epilepsy Curr"},{"key":"10.1016\/j.yebeh.2017.12.017_bb0060","author":"Food and Drug Administration"},{"key":"10.1016\/j.yebeh.2017.12.017_bb0065","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.yebeh.2006.08.008","article-title":"Psychiatric and behavioral side effects of the newer antiepileptic drugs in adults with epilepsy","volume":"10","author":"Weintraub","year":"2007","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2017.12.017_bb0070","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/epi.13054","article-title":"Psychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel","volume":"56","author":"Ettinger","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.12.017_bb0075","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1111\/epi.12212","article-title":"Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies","volume":"54","author":"Steinhoff","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.12.017_bb0080","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/epi.12391","article-title":"Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial","volume":"55","author":"Kwan","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.12.017_bb0085","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/epi.12433","article-title":"Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial","volume":"55","author":"Biton","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.12.017_bb0090","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/epi.12432","article-title":"Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial","volume":"55","author":"Ryvlin","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.12.017_bb0095","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/j.1528-1167.2007.01188.x","article-title":"Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures","volume":"48","author":"Ben-Menachem","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.12.017_bb0100","author":"Hirschfeld"},{"key":"10.1016\/j.yebeh.2017.12.017_bb0105","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1093\/brain\/aww196","article-title":"Psychotic disorders induced by antiepileptic drugs in people with epilepsy","volume":"139","author":"Chen","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.yebeh.2017.12.017_bb0110","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2165\/00002018-200528100-00004","article-title":"Benefit-risk assessment of levetiracetam in the treatment of partial seizures","volume":"28","author":"Abou-Khalil","year":"2005","journal-title":"Drug Saf"},{"key":"10.1016\/j.yebeh.2017.12.017_bb0115","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.82.10_supplement.P3.237","article-title":"Safety of eslicarbazepine acetate in patients with refractory partial-onset seizures treated with or without concomitant carbamazepine: a pooled analysis of three phase III controlled studies","volume":"82","author":"Benbadis","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2017.12.017_bb0125","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/1756285611417920","article-title":"The cognitive impact of antiepileptic drugs","volume":"4","author":"Eddy","year":"2011","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.yebeh.2017.12.017_bb0130","author":"Aptiom\u00ae (Eslicarbazepine Acetate)"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505017303335?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505017303335?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T14:44:57Z","timestamp":1720190697000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505017303335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":25,"alternative-id":["S1525505017303335"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2017.12.017","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psychiatric and cognitive adverse events: A pooled analysis of three phase III trials of adjunctive eslicarbazepine acetate for partial-onset seizures","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2017.12.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}